Basket Updated
0
Items added
U.S. Patent No. 6,441,140, directed to the production of a novel class of motif-specific, context-independent antibodies, highly useful for the identification of subclasses of protein kinase substrates.
Feb 2008, CST continued collaboration with AstraZeneca to provide CST’s PhosphoScan® Platform for kinase inhibitor proteomic profiling.
Aug 2006, CST announced the publication of discovery research based on its patent-pending PhosphoScan® proteomics technology, which identified a mutant JAK3 tyrosine kinase as a novel driver in acute myeloid leukemia (AML).
Nov 2008, Renewal of a research agreement with Ortho-Biotech Oncology Research & Development, under which CST will employ its patented PhosphoScan® and PTMScan® technologies in research aimed at biomarker discovery and validation for multiple enzyme target classes and lead small-molecule inhibitors.
Cell Signaling Technology, a leading provider of antibodies, kits and services, announced today that it has won two Life Science Industry Awards® for "Best Antibodies" and "Most Useful Website."
Feb 2008, CST announced continued PhosphoScan® proteomics research project with Bristol-Myers Squibb for kinase inhibitor profiling.
Jan 2008, CST entered into an assay development partnership agreement with TTP LabTech Ltd. (TTPLT.
Announce partnership with this local 1% for the Planet startup to help share and promote best practices for sustainability. Also, to encourage other companies to do the same by promoting recent sponsorship of NSTC as part of our ESR activities.
Dec 2011, CST wins "Best Performing Antibodies" and "Best Breakthrough Products Cancer Research" Categories in Life Science Industry Awards.
Cell Signaling Technology and Leica Biosystems Partner to Enable Companion Diagnostic (CDx) Development
Cell Signaling Technology (CST), a leading provider of antibodies, kits, and services, was honored with the 2017 CiteAb Award for &quoPTM Antibody Company of the Year" and for a third year in a row with the award for "Researchers’ Choice."
Cell Signaling Technology (CST) Drives Sustainability in the Life Sciences Through My Green Lab Sponsorship
CST and Amoy Diagnostics announced the expansion of their collaboration to use CST antibodies in companion diagnostics to aid growing oncology needs in China.
CiteAb Names Cell Signaling Technology "Antibody Company of the Year" and "Antibody Company Succeeding in Cancer Biology"
What is glycolysis? Glycolysis and oxidative respiration are the two metabolic pathways used to convert biochemical energy into ATP to fuel cell function.
Cell Signaling Technology (CST) Enters Agreement with Roche for CDx Development
CST believes in a data driven approach to continuous improvement and implementation of business practices that minimize negative impact on nature.}{icon: sustainability
Streamline Targeted Protein Degradation Drug Discovery with specific, application-validated antibodies and industry-leading proteomic services.
CiteAb Names Cell Signaling Technology, "Antibody Company of the Year" and "Researchers’ Choice"
CST is proud to partner with global green chemistry nonprofit Beyond Benign to support the creation of green chemistry teaching resources for STEM education.
实验室期望-CST的官方博客,我们将讨论您在工作时的期望,我们将分享提示,技巧和信息,以确保您在工作时的时间达到这些期望。
Use our protocol compatibility table to understand which immune signaling and phenotyping antibodies will work together in your multicolor flow cytometry experiment.
Cell Signaling Technology announces the launch of SignalStar™ Multiplex IHC, a flexible spatial biology solution for up to 8-plex amplification in two days.